scholarly journals Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014

2015 ◽  
Vol 20 (37) ◽  
Author(s):  
Rok Kogoj ◽  
Tatjana Mrvic ◽  
Marina Praprotnik ◽  
Darja Kese
Keyword(s):  
Respiratory Tract ◽  
Mycoplasma Pneumoniae ◽  
Respiratory Tract Infections ◽  
Geographic Area ◽  
Macrolide Resistance ◽  
23S Rrna ◽  
Rrna Gene ◽  
Type I ◽  
Type Ii ◽  
Tract Infections

In this retrospective study we employed real-time polymerase chain reaction (PCR) to analyse the occurrence of Mycoplasma pneumoniae among upper and lower respiratory tract infections (RTI) in the Central Region of Slovenia between January 2006 and December 2014. We also used a culture and pyrosequencing approach to genotype strains and infer their potential macrolide resistance. Of a total 9,431 tested samples from in- and out-patient with RTI, 1,255 (13%) were found to be positive by M. pneumoniae PCR. The proportion of positive samples was 19% (947/5,092) among children (?16 years-old) and 7% (308/4,339) among adults (>16 years-old). Overall, among those PCR tested, the highest proportions of M. pneumoniae infections during the study period were observed in 2010 and 2014. In these two years, 18% (218/1,237) and 25% (721/2,844) of samples were positive respectively, indicating epidemic periods. From the 1,255 M. pneumoniae PCR-positive samples, 783 (614 from paediatric and 169 from adult patients) were successfully cultured. Of these, 40% (312/783) were constituted of strains belonging to the P1 type II genomic group, while 60% (469/783) contained strains of the P1 type I group. Two isolates comprised both P1 type I and II strains. Results of a genotype analysis by year, showed that the dominant M. pneumoniae P1 type during the 2010 epidemic was P1 type II (82% of isolates; 81/99), which was replaced by P1 type I in the 2014 epidemic (75%; 384/510). This observation could indicate that the two epidemics may have been driven by a type shift phenomenon, although both types remained present in the studied population during the assessed period of time. Only 1% of strains (7/783) were found to harbour an A2063G mutation in the 23S rRNA gene, which confers macrolide resistance, suggesting that the occurrence of M. pneumoniae macrolide resistance still seems to be sporadic in our geographic area.

scholarly journals Molecular Mechanisms of Macrolide Resistance in Clinical Isolates of Mycoplasma pneumoniae from China

2009 ◽  
Vol 53 (5) ◽  
pp. 2158-2159 ◽  
Author(s):  
Deli Xin ◽  
Zuhuang Mi ◽  
Xu Han ◽  
Ling Qin ◽  
Jing Li ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Molecular Mechanism ◽  
Mycoplasma Pneumoniae ◽  
Respiratory Tract Infections ◽  
Molecular Mechanisms ◽  
Point Mutations ◽  
Macrolide Resistance ◽  
The Other ◽  
23S Rrna ◽  
Tract Infections

ABSTRACT Fifty clinical Mycoplasma pneumoniae strains were isolated from 370 children with respiratory tract infections. Four strains were susceptible to macrolides, while the other 46 (92%) were macrolide resistant. The molecular mechanism of resistance was shown to be associated with point mutations in 23S rRNA at positions 2063 and 2064.

scholarly journals Macrolide Resistance, Clinical Features, and Cytokine Profiles in Taiwanese Children with Mycoplasma pneumoniae Infection

2021 ◽  
Author(s):  
Tsung-Hua Wu ◽  
Nancy M Wang ◽  
Fang-Ching Liu ◽  
Hui-Hsien Pan ◽  
Fang-Liang Huang ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Mycoplasma Pneumoniae ◽  
Clinical Characteristics ◽  
Respiratory Tract Infections ◽  
Macrolide Resistance ◽  
Clinical Severity ◽  
Cytokine Profiles ◽  
Mlva Type ◽  
Tract Infections ◽  
Mycoplasma Pneumoniae Infection

Abstract Background The factors to predict the progression of Mycoplasma pneumoniae infection remain inconclusive. Therefore, we investigated macrolide resistance prevalence, M. pneumoniae genotype, and clinical characteristics of childhood M. pneumoniae respiratory tract infections in Taiwan. Methods A total of 295 children hospitalized with respiratory tract infections with positive serological M. pneumoniae immunoglobulin M test results were enrolled in this 3-year prospective study. Oropharyngeal swabs were obtained for M. pneumoniae cultures and PCR tests. All M. pneumoniae specimens were further characterized by P1 typing, multilocus variable-number tandem-repeat analysis (MLVA), and macrolide resistance genotyping. The clinical characteristics and blood cytokine profiles were analyzed accordingly. Results Of 138 M. pneumoniae specimens, type I P1 was the predominant (136/138, 98.6%). MLVA type P (4-4-5-7-2) was the leading strain (42/138, 30.4%), followed by type J, U, A, and X. The overall macrolide-resistant rate was 38.4% (53/138); the resistance rate increased dramatically yearly: 10.6% in 2017, 47.5% in 2018, and 62.5% in 2019 (P < .001). All macrolide-resistant M. pneumoniae (MRMP) harbored the A2063G mutation and were MLVA type 4-5-7-2 (49/53, 92.5%), especially type U and X. No significant differences in clinical symptoms, duration of hospital stay, and radiographic findings were identified among patients between MRMP and macrolide-sensitive M. pneumoniae (MSMP) groups. Patients with MRMP infection had more febrile days before and during hospitalization; higher IL-13 and IL-33 levels than patients with MSMP infection (P < .005). Conclusions MRMP surged in Taiwan throughout the study period, but macrolide resistance was not a determinant factor of clinical severity.

scholarly journals A study of community-acquired Mycoplasma pneumoniae in Yantai, China

2018 ◽  
Vol 49 (2) ◽  
pp. 160-163
Author(s):  
Hong-Xia Yu ◽  
Mao-Mao Zhao ◽  
Zeng-Hui Pu ◽  
Yuan-Rong Ju ◽  
Yan Liu
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Community Acquired Pneumonia ◽  
Macrolide Resistance ◽  
23S Rrna ◽  
Diagnostic Tools ◽  
Rrna Gene ◽  
Resistance Mutations ◽  
First Line ◽  
Tract Infections

Introduction: Community-acquired pneumonia (CAP) is a global disease responsible for a large number of deaths, with significant economic impact. As diagnostic tools have increased in sensitivity, understanding of the etiology of CAP has begun to change. Mycoplasma pneumoniae is one of the major pathogens causing CAP. Macrolides and related antibiotics are first-line treatments for M. pneumoniae. Macrolide resistance has been spreading for 15 years and now occurs in worldwide. We undertook the first study on macrolide resistance of M. pneumoniae in Yantai. This may be helpful to determine the appropriate therapy for CAP in this population. Objective: To investigate the rate and mechanism of macrolide resistance in Yantai. Methods: Pharyngeal swab samples were collected from adult CAP patients. Samples were assayed by polymerase chain reaction (PCR) and cultivated to test for M. pneumoniae. Nested PCR was used to specifically amplify M. pneumoniae 23S rRNA gene fragments containing mutations, and amplicons were analyzed by CE-SSCP for macrolide resistance mutations. Results were confirmed by sequencing. Twenty-seven strains of M. pneumoniae were isolated and the activities of nine antibiotics against M. pneumoniae were tested in vitro. Results: Out of 128 samples tested, 27 were positive for M. pneumoniae. Mycoplasma 100% macrolides resistance to Mycoplasma pneumoniae. The mechanism of macrolides resistance was A2063G point mutation in the sequence directly binding to macrolides in the 23S rRNA V domain in vitro. The mean pyretolytic time for the fluoroquinolone group was 4.7 ±2.9 d, which was significantly shorter than 8.2 ±4.1 d for the azithromycin group. Conclusions: Macrolides are not the first-line treatment for M. pneumoniae respiratory tract infections in Yantai.

scholarly journals Associations Between IFI44L Gene Variants and Rates of Respiratory Tract Infections During Early Childhood

2020 ◽  
Vol 223 (1) ◽  
pp. 157-165
Author(s):  
Johanna Lempainen ◽  
Laura S Korhonen ◽  
Katri Kantojärvi ◽  
Santtu Heinonen ◽  
Laura Toivonen ◽  
...  
Keyword(s):  
Early Childhood ◽  
Respiratory Tract ◽  
Otitis Media ◽  
Respiratory Tract Infections ◽  
Acute Otitis Media ◽  
Respiratory Viruses ◽  
Birth Cohort Study ◽  
Type I ◽  
Gene Variants ◽  
Tract Infections

Abstract Background Genetic heterogeneity in type I interferon (IFN)–related gene IFI44L may account for variable susceptibility to respiratory tract infections (RTIs) in children. Methods In 2 prospective, population-based birth cohorts, the STEPS Study and the FinnBrain Birth Cohort Study, IFI44L genotypes for rs273259 and rs1333969 were determined in relation to the development of RTIs until 1 or 2 years of age, respectively. At age 3 months, whole-blood transcriptional profiles were analyzed and nasal samples were tested for respiratory viruses in a subset of children. Results In the STEPS Study (n = 1135), IFI44L minor/minor gene variants were associated with lower rates of acute otitis media episodes (adjusted incidence rate ratio, 0.77 [95% confidence interval, .61–.96] for rs273259 and 0.74 [.55–.99] for rs1333969) and courses of antibiotics for RTIs (0.76 [.62–.95] and 0.73 [.56–.97], respectively. In the FinnBrain cohort (n = 971), IFI44L variants were associated with lower rates of RTIs and courses of antibiotics for RTIs. In respiratory virus–positive 3-month-old children, IFI44L gene variants were associated with decreased expression levels of IFI44L and several other IFN-related genes. Conclusions Variant forms of IFI44L gene were protective against early-childhood RTIs or acute otitis media, and they attenuated IFN pathway activation by respiratory viruses.

Sign in / Sign up

Export Citation Format

Share Document